NCT01557127View on ClinicalTrials.gov

"Nexavar Dosing in Renal Cancer Patients in Real-life Setting"

CompletedOBSERVATIONAL

Enrollment

205

Participants

Timeline

Start Date

November 1, 2011

Primary Completion Date

May 16, 2014

Study Completion Date

March 31, 2016

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid)

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY